Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) nej.md/4p6tIDo Editorial: Art within Evidence — Balancing Anticoagulant Duration in VTE Care nej.md/3HDriLB #Hematology

🧵 Eculizumab in Hematology – Full Review (ASTCT/EBMT/ASH 2024-25) ⸻ 1️⃣ 💉 Drug Class & Mechanism •Humanized IgG2/4 mAb vs C5 → blocks cleavage to C5a & C5b •Prevents MAC (C5b-9) formation → ↓ complement-mediated hemolysis & endothelial injury ⸻ 2️⃣ 📦 FDA-Approved

🧵 TMA – MCQs & OSCEs for Hema Fellows 🩸 (Focus: HSCT/SOT-associated TMA • PNH • aHUS • TTP) ⸻ 🔥 MCQs with Answers 1️⃣ MCQ Adult HSCT Day +40, MAHA + thrombocytopenia, LDH ↑, Coombs negative, creat ↑, BP ↑, ADAMTS13 = 65% Best next step? A) Start PLEX B) Start

🧵 Hematology – Chemotherapy Requiring Central Venous Access (To avoid extravasation, ensure reliable infusion, often via PICC, port, or Hickman line) ⸻ 1️⃣ Vesicant Anthracyclines 💉🔥 •Doxorubicin, Daunorubicin, Idarubicin, Epirubicin •High risk of tissue necrosis if

🧵 Falls Precautions – Pearls for Hematology Units 🩸🚶‍♂️ (Key for BMT, cytopenic, elderly hema patients – ward & clinic safety) ⸻ 1️⃣ 🔎 High-Risk Groups •Thrombocytopenia (<20–30 × 10⁹/L) 🩸 •Anemia (Hb <8 g/dL) •Steroid-induced myopathy 💪 •Peripheral neuropathy

🧵 T-ALL (T-Cell Acute Lymphoblastic Leukemia) – Hema-Fellows Core Pearls 🩸 (Adult focus • ASH/NCCN 2024-25) ⸻ 1️⃣ 🔎 Overview •Aggressive precursor T-lymphoblast malignancy •20–25% of adult ALL •Often presents with high WBC, bulky mediastinal mass, TLS, CNS involvement

🧵 Eltrombopag – Dosing & Adjustment 🩸 (Adult Hematology • ITP / AA / post-HSCT cytopenia – ASH/NCCN 2024-25) ⸻ 1️⃣ 💊 Mechanism •Oral TPO-Receptor Agonist → ↑ platelet production •Used in chronic ITP, severe aplastic anemia (SAA), post-HSCT thrombocytopenia ⸻ 2️⃣ 📦

🧵 Avatrombopag – Hema-Fellows Review 🩸 (Adult focus • Chronic ITP / Post-HSCT thrombocytopenia – ASH/NCCN 2024-25) ⸻ 1️⃣ 🔎 Overview •Oral, non-peptide TPO-Receptor Agonist •Stimulates megakaryocyte proliferation & platelet production •FDA-approved for:   • Chronic ITP

🧵 Hemophilia B – Hema-Fellows Core Review 🩸 (Adult focus • ASH/WFH 2024-25) ⸻ 1️⃣ 🔎 Definition •X-linked congenital deficiency of Factor IX (FIX) •Accounts for 15–20% of all hemophilia •Classified by baseline FIX activity:   • Severe: <1%   • Moderate: 1–5%   • Mild:

#ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC USMIRC News OncoAlert #سرطان_الدم #المايلوما CancerNetwork® @kucancercenter